Vyant Bio (VYNT) 10-Q2017 Q3 Quarterly report

Filed: 13 Nov 17, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Good

New words: abroad, accommodate, accurately, aimed, alter, animal, announced, assimilating, assist, assumption, attack, attention, authorization, avoid, backlog, bear, Binomial, bioanalytical, bolstering, breach, broad, broader, budgetary, called, cancel, cancellation, capture, Carlo, cell, Center, certainty, chemical, civil, claim, competitor, complex, compound, compromise, compromised, concentration, conduct, conducting, confidentiality, consummate, contemplated, contemplating, contract, contractual, contractually, country, coverage, criminal, criteria, CRO, currency, cyber, cyberattack, damage, declined, deepen, defending, depreciation, detail, diminished, disqualification, disrupt, disruption, dissemination, diversion, documentation, documenting, downstream, Economic, efficacy, electronic, endeavor, enforcement, entail, environmental, ethical, EU, explicit, face, fail, failure, fewer, final, flaw, forced, forego, foreign, forma, forty, franchise, Germany, global, governing, government, hacking, harm, harmed, Hershey, HIPAA, HITECH, human, imaging, implement, improper, improperly, inability, inappropriate, IND, indirectly, infrastructure, inquiry, intangible, interfere, investigated, Investigation, Investigational, Japan, Korea, lack, legislation, leukemia, liable, library, liver, local, lung, Malaysia, malware, mammalian, managerial, member, mishandling, Monte, Munich, natural, notification, obviate, orthotopic, outcome, overrun, pancreatic, parameter, PDx, Pennsylvania, pharmacology, phase, Portability, practicable, preferred, prevailing, prevent, preventive, previously, privacy, pro, prohibition, proposed, prosecution, prove, rare, rebuilding, recurrence, reliability, reliable, rely, remedial, remedy, repeat, repurposing, reputation, reputational, rescue, resolve, resource, respond, responding, revoke, Russia, safety, satisfaction, scheme, screening, scrutiny, sensitive, shift, shut, Singapore, size, South, stage, store, strain, stronger, submission, suffer, syngeneic, tangible, theft, therapeutic, toxicology, translated, translation, typically, unauthorized, underprice, underpricing, undesired, unexpected, unsuccessful, variety, verify, vitro, vivo, winding, xenograft

Removed: probe

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated VYNT transcripts

VYNT similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Cancer Genetics, Inc. (the “Company”) on Form 10-Q for the quarter ended September 30, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Panna L. Sharma, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 13, 2017

/s/ Panna L. Sharma

Panna L. Sharma

President and Chief Executive Officer

(Principal Executive Officer)

The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.